OLMA · Nasdaq · CIK 0001750284

Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc.’s most recent SEC filing in our snapshot is a Form SCHEDULE 13D/A filed on Oct 16, 2026. Its EDGAR record lists 32 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-$162.5M
Form 4 filings on record, past 12 months
32

Company overview

Legal name (as filed)
Olema Pharmaceuticals, Inc.
Ticker
OLMA
SEC Central Index Key (CIK)
0001750284
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
SAN FRANCISCO, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2789 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Olema Pharmaceuticals, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-$71.1MFY2021-$104.8MFY2022-$96.7MFY2023-$129.5MFY2024-$162.5MFY2025
OLMA annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net income-$71.1M-$104.8M-$96.7M-$129.5M-$162.5M
Diluted EPS-$1.80-$2.62-$2.14-$2.20-$1.87
Total assets$295.9M$215.6M$276.9M$451.0M$533.4M
Cash and equivalents$13.8M$23.7M$68.5M$139.5M$48.3M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

OLMA latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 16, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Oct 15, 20268-KDirector or officer change· period Oct 12, 2026Document · Index
Apr 29, 2026DEF 14ADefinitive proxy statement· period Apr 29, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Olema Pharmaceuticals, Inc., by form type:

4 ×148-K ×9144 ×4SCHEDULE 13G/A ×43 ×210-Q ×2SCHEDULE 13D/A ×1ARS ×1DEFA14A ×1DEF 14A ×1SCHEDULE 13G ×1
OLMA recent filings
FiledFormWhat it isOriginal
Oct 16, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Oct 15, 20268-KDirector or officer change· period Oct 12, 2026Document · Index
Sep 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 1, 2026Document · Index
Aug 13, 20263Initial statement of beneficial ownership· period Aug 11, 2026Document · Index
Aug 13, 20268-KDirector or officer change; Regulation FD disclosure· period Aug 13, 2026Document · Index
Aug 10, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 10, 20268-KResults of operations· period Aug 10, 2026Document · Index
Aug 6, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 29, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 27, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 23, 2026Document · Index
Jul 24, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 23, 2026144Notice of proposed sale of securitiesDocument · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20268-KShareholder vote results· period Jun 17, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
Jun 23, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 18, 2026Document · Index
May 26, 20268-KRegulation FD disclosure; Other events· period May 26, 2026Document · Index
May 21, 20268-KRegulation FD disclosure; Other events· period May 21, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 12, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 12, 20268-KResults of operations· period May 12, 2026Document · Index
May 1, 20268-KMaterial agreement; New financial obligation· period Apr 27, 2026Document · Index
Apr 29, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 28, 2026Document · Index
Apr 29, 20263Initial statement of beneficial ownership· period Apr 28, 2026Document · Index
Apr 29, 2026ARSARS· period Dec 31, 2025Document · Index
Apr 29, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 29, 2026DEF 14ADefinitive proxy statement· period Apr 29, 2026Document · Index
Apr 29, 20268-KDirector or officer change; Regulation FD disclosure· period Apr 27, 2026Document · Index
Mar 20, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Mar 16, 2026144Notice of proposed sale of securitiesDocument · Index
Mar 16, 2026144Notice of proposed sale of securitiesDocument · Index

Insider filing activity

32 Form 4 filings appear in Olema Pharmaceuticals, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001750284 and XBRL company facts. Olema Pharmaceuticals, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.